PICOSSIDE (0.4.1)
Approved for use through 07/13/2006 (0.40) 054-030.

U.S. Peletra att (1/sekmaik Orlocy U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of infamination unless of contains a value of the contains and unless of contains a value.

	Application Number			
NEODMATION DIGGI COURT	Filing Date		2006-06-14	
NFORMATION DISCLOSURE STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	First Named Inventor OUE		ELID ABDESSELEM	
	Art Unit			
	Examiner Name			
	Attorney Docket Numb	er	CS23899P	

U.S.PATENTS							Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Releva		Lines where ges or Relevan	
	1	6560456	B1	2003-05-06	LOHTIA ET AL.				
	2	6505046	B1	2003-01-07	BAKER				
	3	6798358	B2	2004-09-28	JOYCE ET AL.				
	4	6529942	B1	2003-03-04	GILBERT				
If you wis	h to a	dd additional U.S. Pater	t citatio	n information p	lease click the Add button.		Add		
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove		
Examiner Initial*			Name of Patentee or Applicant of cited Document	Releva	Columns, int Passag s Appear	Lines where ges or Relevan			
	1	20010034767	A1	2001-10-25	AHO				
	2	20030086438	A1	2003-05-08	LAUMEN ET AL.				
If you wis	h to a	dd additional U.S. Publis	hed Ap	plication citatio	n information please click the Ad	d button	Add		
				CODEICH DA	TENT DOCUMENTS		Remove		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Foreign Document

Examiner Cite

No Number³

Initial*

Application Number			
Filing Date		2006-06-14	
First Named Inventor	OUELID ABDESSELEM		
Art Unit			
Examiner Name			
Attorney Docket Number		CS23899P	

Name of Patentee or

Date Considered

Applicant of cited

Document

Pages, Columns, Lines

where Relevant Passages or Relevant

Figures Appear

		1	02054902	wo	A1	2002-07-11	FU-TURICE OY		
		2	03017077	wo	A1	2003-02-27	NOKIA CORPORATION		
		3	9920014	wo	A2	1999-04-22	NOVEMAIL SYSTEM AB		
Ī	f you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add button	n Add	
NON-PATENT LITERATURE DOCUMENTS Remove									
	Examiner initials* Cite (hock, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, etc) and or country where published.						Ţ5		
Γ									

Kind Publication

Code⁴ Date

Country

Code2 i

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a 1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST 3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. 5 Applicant is to place a check mark here if

If you wish to add additional non-patent literature document citation information please click the Add button Add EXAMINER SIGNATURE

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature

English language translation is attached.

Application Number Filing Date 2006-06-14 First Number INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1-99) Art Unit Examiner Name Attorney Docket Number I CS238999 Attorney Docket Number I CS23899 Attorney Docket Number I CS238999 Attorney Docket Number I CS23899 Attorney D

CERTIFICATION STATEMENT

Please see 3	7 CFR 1	1.97 and	1.98 to make t	the appropriate selection(s):	
--------------	---------	----------	----------------	-------------------------------	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/t1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.39(c) and the statement. See 37 CFR 1.39(c) and the statement. See 37 CFR 1.39(c) and the statement. See

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- .7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Sylvia Chen/	Date (YYYY-MM-DD)	2006-06-14
Name/Print	SYLVIA CHEN	Registration Number	39.633

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is fol file and by the USPTO to process) an application. Confidentiality is governed by 35 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, u.S. Operatment of Commence, P. 0. Bot 1450, Alexandria, V.32.11.450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.32.211.4150.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolffice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or of reduced now a submission or the sales to process another examines your submission, which may visually intermediate or of reduced now a submission of the sales to process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via yet of sciences, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via self or in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.